Enquirer Consulting Group

Reachable Buyer Map

Prepared for Robert Poe · Olon USA · August 2026
This map covers the United States. In this market, a development and manufacturing relationship usually begins one of three ways: the next molecule from a customer already on the books, a conversation at a partnering conference, or a request that arrives already shaped by whoever helped write it. All three reach companies that already know the name. Here is the layer outside that: the groups that buy small molecule chemistry, who signs inside each one, and roughly how many there are.
Commercial-stage pharmaceutical companies
The group with a supply chain already running and a standing reason to qualify a second source. Slow to move and durable once inside, because a supplier written into a filing tends to stay there for the life of the product.
Who signs: VP of technical operations, head of external manufacturing, director of CMC, supply chain or procurement lead, and quality on the audit.
2,400 to 2,900
US employers registered in pharmaceutical and medicine production, of which roughly 700 to 900 carry 100 or more people on the plan
Clinical-stage and venture-backed biotech
The fastest moving group on this page and the least visible, because development stage is not a field anyone files. Teams here outsource nearly all of their chemistry, and the decision usually sits with two or three people rather than a committee.
Who signs: chief scientific officer, head of CMC, VP of technical operations, and the chief executive at founder-led companies.
800 to 900
US research and development companies with payroll on file, roughly 220 to 260 of them at 250 or more people; stage is not a filed field, so the virtual end of this group is reached by published pipeline rather than by list
Generic and specialty drug makers
The buyer that treats chemistry as a cost line rather than a science project, which shortens the conversation and hardens it. Second-source qualification and a site change are the two moments that reopen an incumbent.
Who signs: head of procurement, VP of supply chain, head of regulatory affairs, site or plant director.
Roughly 7,700 firm names
on the federal drug establishment register, which is worldwide and includes sites outside the United States, so the US layer is a subset of it
Specialty and performance chemical companies
A customer group you name publicly alongside pharma, and a different sale entirely. Volumes are larger, the regulatory weight is lighter, and qualification runs on cost and consistency rather than on filings.
Who signs: head of sourcing, R&D director, product line manager, operations director.
Several thousand
US employers registered across chemical production; the specialty and performance layer inside that is self-coded and not broken out separately, so it is identified rather than filtered
Development services firms and research organizations
Not an end user, a route to several. A firm that runs the biology and hands the chemistry on already holds the customer relationship, which makes this a referral layer rather than a target list.
Who signs: scientific director, VP of operations, head of business development, program manager.
3,000 to 3,600
US employers registered as testing laboratories and research services; the drug development subset is a fraction of that and is not separately coded
Federally funded small companies
The most predictable calendar on this page, because award dates are published and the money arrives with a scope attached. A company funded for a preclinical program has a chemistry problem and a deadline in the same week.
Who signs: founder or chief executive, principal investigator, head of research operations.
1,600 to 1,800 a year
federal small business awards to US companies across all fields; an award count rather than a company count, since one company can hold several

Where the openings are

1
The counted groups above come to roughly 6,200 to 7,400 US employers. The other three are left out of that total on purpose, because the registers that hold them do not separate the layer that matters. In this market, growth usually reaches whichever slice of that already knows the name, through a customer's next molecule, a partnering conference or an inbound request. The rest is not unqualified. It is unaware.
2
The buyer here is a seat, not a company. Head of external manufacturing, head of CMC, VP of technical operations. Those seats turn over, and a new one almost always reopens the supplier list. Reach built on named roles catches that window. Reach built on the conference calendar hears about it once the decision is made.
3
The clinical-stage layer is the one lists under-work. Development stage is not filed anywhere, so a purchased list of pharmaceutical companies returns plants and holding entities and misses the small teams that outsource everything. Working that layer takes identification rather than purchase, which is exactly why it stays open.
4
Two different sales sit on this page. Regulated pharmaceutical chemistry is bought by technical operations and quality. Specialty and performance chemicals are bought by sourcing and product. One channel tends to keep knocking on the same door. Two named audiences is a different reach problem, and a solvable one.
Built from public federal registry data covering US employers that file a benefit plan, current to the 2024 filing year, alongside the federal drug establishment register and federal award records. Counts are banded deliberately. Employer counts use plan participants as a headcount proxy and exclude owner-only and very small companies, sector codes are self-reported, the drug establishment register is worldwide rather than US only, and award counts are awards rather than companies. It describes the market rather than your business, and there is nothing to buy at the end of it.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com